Gene On Biotech, Inc.

GeneOnBiotech (진온바이오텍)

Gene On Biotech

Company Profile: Gene On Biotech, Inc.
Overview
Gene On Biotech is a South Korean bio-health startup specializing in AI-driven drug discovery fused with Quantum Computing and Proteomics. Unlike competitors relying solely on AI predictions, Gene On Biotech integrates wet-lab validation using its proprietary 20,000-human-protein microarray, bridging the gap between digital simulation and biological reality. Their flagship platform, QUAI, accelerates the development of peptide therapeutics, targeting high-demand sectors like hair loss and intractable diseases.

Field
Information
Company Name
Gene On Biotech, Inc. (진온바이오텍)
CEO
Hakjin Kim (김학진)
Headquarters
Daejeon, South Korea
Website
www.geneon.kr/eng
CES 2026 Location
Venetian Expo, Hall G — #62845 (Eureka Park)
Core Technology
QUAI Platform (Proteomics + AI + Quantum Computing)
Key Achievement
Discovery of Elixiah, a peptide candidate for hair loss therapy (PoC completed)

Key Competitiveness & Technology
* QUAI Platform: A hybrid drug discovery engine that combines:
* Proteomics: Proprietary microarray chips containing ~20,000 human proteins for high-throughput screening.
* AI (Artificial Intelligence): Generative models for peptide design and optimization.
* Quantum Computing: Utilization of VQE (Variational Quantum Eigensolver) algorithms to simulate molecular interactions with high precision, integrated with IBM Quantum, Google Quantum AI, and Amazon Braket resources.
* Validation Advantage: Capable of validating AI predictions immediately via their in-house protein microarray, reducing false positives common in AI-only approaches.
* Performance: Claims to reduce R&D time by 90% and costs by 10x compared to traditional methods.
Recent Developments & Media Highlights
* Hair Loss Therapy (Elixiah): Successfully identified a peptide candidate for hair loss treatment using the QUAI platform. The candidate demonstrated high binding specificity (92%) and reduced off-target effects.
* Scientific Validation: Research results and Proof of Concept (PoC) for Elixiah and other candidates have been supported by publications in high-impact journals such as Nature Signal Transduction and Targeted Therapy (STTT).
* Global Collaboration: Currently conducting joint R&D with major institutions including Johns Hopkins University, University of Cambridge, and KRIBB (Korea Research Institute of Bioscience and Biotechnology).

Strategic Opportunities: Potential Partners at CES 2026
Based on Gene On Biotech’s focus on AI drug discovery, Quantum Computing, and Digital Health, the following exhibitors are high-value targets for partnership, infrastructure support, or collaborative R&D.
1. R&D & Technology Institutes (High Priority)
These organizations focus on deep-tech validation, nano-electronics, and digital health ecosystems, offering potential for joint research or technology licensing.

• IMEC (Nanoelectronics & Digital Tech Research)

• Relevance: World-leading R&D hub in nanoelectronics and digital health. Potential partner for sensor integration or advanced computing hardware for bio-applications.

• Booth: Venetian Expo, Halls A-D — 50328 (Note: Location may vary, check specific listing)

• Detail Page: View IMEC on CES Website

• CSEM SA (Swiss Technology Innovation Center)

• Relevance: Specializes in precision manufacturing and digital health technologies. Could be a partner for developing hardware interfaces for Gene On's diagnostic arrays.

• Booth: Venetian Expo, Halls A-D — 54306
• Detail Page: View CSEM on CES Website

• AI & Computing Infrastructure
  Partners to support the high-performance computing (HPC) and quantum simulation needs of the QUAI platform.

• Microsoft

• Relevance: Provider of Azure Quantum and AI infrastructure. Strategic partnership opportunity for cloud computing resources.

• Detail Page: View Microsoft on CES Website

• Qualcomm

• Relevance: Leader in edge AI computing. Potential for on-device AI processing partnerships for future diagnostic devices.

• Booth: LVCC, West Hall — 5001

• Detail Page: View Qualcomm on CES Website

• Quantum Computing Inc.

• Relevance: Pioneers in quantum photonics for advanced computing. Directly relevant to Gene On's quantum algorithmic approach.

• Detail Page: View Quantum Computing Inc. on CES Website

• Synergistic AI Bio/Health Startups
  Companies with complementary technologies for potential co-development or M&A targets.

• Portrai Inc.

• Relevance: Specializes in AI spatial biology and drug discovery. Potential synergy in combining their spatial analysis with Gene On's proteomic data.

• Booth: Venetian Expo, Hall G — 62949

• Detail Page: View Portrai Inc. on CES Website

• Argeron Medikal

• Relevance: Focuses on biological age assessment and IVD kits (biomarkers). Potential collaboration on biomarker discovery using Gene On's arrays.

• Booth: Venetian Expo, Hall G — 63432
• Detail Page: View Argeron Medikal on CES Website
• Strategic Consulting & Investment
• McKinsey & Company
• Relevance: Global strategy consulting with a strong focus on AI and biotech. Useful for scaling strategies and connecting with big pharma.
• Booth: LVCC, West Hall Mtg Rms — W321
• Detail Page: View McKinsey on CES Website